Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

ProBio Establishes Hopewell, New Jersey, Gene Therapy Operations

07/02/2025
ProBio, a contract development and manufacturing organization, has established operations in Hopewell, New Jersey. The project is expected to create 110 jobs.

The company’s new 128,000-square-foot Cell and Gene Therapy Center of Excellence is located at the Princeton West Innovation Campus and will manufacture plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms.

"This is not just a new facility. It is a beacon of hope for patients waiting for cures," said Allen?Guo, CEO of ProBio. "Opening the Hopewell center is a milestone in ProBio's global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions."

ProBio aims to accelerate the manufacturing of life-changing drugs, discover novel therapeutic targets, and develop innovative therapeutic approaches to manufacture best-in-class DNA, RNA, and protein-based therapeutics. The company brings together multi-disciplinary expertise to accelerate the manufacturing of advanced therapies, including biologics, protein and mRNA vaccines, viral vectors, antibody-drug conjugates and drug discovery services.

"The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field,” noted John Coelho, Senior Advisor, New Jersey Economic Development Authority. “The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients."

Exclusive Research